Expertise in
49
conditions

Dr. Robert M. Conry

Oncology
Anniston Oncology
901 Leighton Ave Ste 602, 
Anniston, AL 
Accepting New Patients
Expertise in
49
conditions
Anniston Oncology
901 Leighton Ave Ste 602, 
Anniston, AL 

Overview

Robert Conry is an Oncologist practicing medicine in Anniston, Alabama.

Dr. Conry is highly rated in 49 conditions, according to our data. His clinical expertise encompasses Melanoma, Adult Soft Tissue Sarcoma, Rhabdomyosarcoma, and Alveolar Soft Part Sarcoma.

He is actively involved in clinical research, co-authoring 45 peer reviewed articles and participating in 12 clinical trials. Dr. Conry is currently accepting new patients.

Specialties

Oncology

Licenses

Internal Medicine in AL

Hospital Affiliations

Northeast Alabama Regional Medical Center

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
VIVA Health
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 5 Less Insurance Carriers -

Locations

Anniston Oncology
901 Leighton Ave Ste 602, Anniston, AL 36207

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

12 Clinical Trials

DREAMseq (Doublet, Randomized Evaluation in Advanced Melanoma Sequencing) a Phase III Trial
DREAMseq (Doublet, Randomized Evaluation in Advanced Melanoma Sequencing) a Phase III Trial
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Other, Procedure, Biological, Drug
Study Drugs: Dabrafenib Mesylate, Ipilimumab, Nivolumab, Trametinib Dimethyl Sulfoxide
Study Phase: Phase 3
Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients With Unresectable Stage III or Stage IV Melanoma
Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients With Unresectable Stage III or Stage IV Melanoma
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Procedure, Biological
Study Drugs: Ipilimumab, Nivolumab, Sargramostim
Study Phase: Phase 2/Phase 3
A Randomized Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAF V600E/K Mutant Melanoma
A Randomized Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAF V600E/K Mutant Melanoma
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Procedure, Drug
Study Drugs: Dabrafenib Mesylate, Trametinib Dimethyl Sulfoxide
Study Phase: Phase 2
A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients With High Risk Resected Melanoma
A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients With High Risk Resected Melanoma
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Other, Procedure, Biological
Study Drugs: Ipilimumab, Pembrolizumab, Recombinant Interferon Alfa-2b
Study Phase: Phase 3
A Phase II Randomized Study of Adjuvant Versus NeoAdjuvant Pembrolizumab (MK-3475) for Clinically Detectable Stage III-IV High-Risk Melanoma
A Phase II Randomized Study of Adjuvant Versus NeoAdjuvant Pembrolizumab (MK-3475) for Clinically Detectable Stage III-IV High-Risk Melanoma
Enrollment Status: Active_not_recruiting
Publish Date: August 04, 2026
Intervention Type: Procedure, Biological
Study Drug: Pembrolizumab
Study Phase: Phase 2
Phase II Randomized Trial of Avelumab Plus Cetuximab Versus Avelumab Alone in Advanced Cutaneous Squamous Cell Carcinoma of the Skin (cSCC)
Phase II Randomized Trial of Avelumab Plus Cetuximab Versus Avelumab Alone in Advanced Cutaneous Squamous Cell Carcinoma of the Skin (cSCC)
Enrollment Status: Active_not_recruiting
Publish Date: June 02, 2026
Intervention Type: Drug
Study Drugs: Avelumab, Cetuximab
Study Phase: Phase 2
An Open-Label, Multicenter, Phase 1/2 Study of RP1 as a Single Agent and in Combination With PD1 Blockade in Patients With Solid Tumors [IGNYTE]
An Open-Label, Multicenter, Phase 1/2 Study of RP1 as a Single Agent and in Combination With PD1 Blockade in Patients With Solid Tumors [IGNYTE]
Enrollment Status: Active_not_recruiting
Publish Date: February 13, 2026
Intervention Type: Biological
Study Drugs: RP1, Nivolumab
Study Phase: Phase 2
A Randomized Phase II Trial of Ipilimumab With or Without Bevacizumab in Patients With Unresectable Stage III or Stage IV Melanoma
A Randomized Phase II Trial of Ipilimumab With or Without Bevacizumab in Patients With Unresectable Stage III or Stage IV Melanoma
Enrollment Status: Completed
Publish Date: December 11, 2025
Intervention Type: Biological
Study Drugs: Bevacizumab, Ipilimumab
Study Phase: Phase 2
A Prospective, Randomized, Blinded, Placebo-controlled, Phase IIb Trial of an Autologous Tumor Lysate (TL) + Yeast Cell Wall Particles (YCWP) + Dendritic Cells (DC) Vaccine vs Unloaded YCWP + DC and Embedded Phase I/IIa Trial With Tumor Lysate Particle Only (TLPO) Vaccine in Stage III and Stage IV (Resected) Melanoma to Prevent Recurrence.
A Prospective, Randomized, Blinded, Placebo-controlled, Phase IIb Trial of an Autologous Tumor Lysate (TL) + Yeast Cell Wall Particles (YCWP) + Dendritic Cells (DC) Vaccine vs Unloaded YCWP + DC and Embedded Phase I/IIa Trial With Tumor Lysate Particle Only (TLPO) Vaccine in Stage III and Stage IV (Resected) Melanoma to Prevent Recurrence.
Enrollment Status: Completed
Publish Date: November 29, 2024
Intervention Type: Drug
Study Drug: Tumor Lysate, Particle-Loaded, Dendritic Cell Vaccine
Study Phase: Phase 2
Multi-center Phase I/IIa Trial of an Autologous Tumor Lysate (TL) + Yeast Cell Wall Particles (YCWP) + Dendritic Cells (DC) Vaccine in Addition to Standard of Care Checkpoint Inhibitor of Choice in Metastatic Melanoma Patients With Measurable Disease.
Multi-center Phase I/IIa Trial of an Autologous Tumor Lysate (TL) + Yeast Cell Wall Particles (YCWP) + Dendritic Cells (DC) Vaccine in Addition to Standard of Care Checkpoint Inhibitor of Choice in Metastatic Melanoma Patients With Measurable Disease.
Enrollment Status: Completed
Publish Date: March 12, 2024
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
View 9 Less Clinical Trials

45 Total Publications

Phase 2, Open-Label, Multicenter Study of Nelitolimod in Combination with Pembrolizumab in Anti-PD-1 Treatment-Naïve Advanced Melanoma.
Phase 2, Open-Label, Multicenter Study of Nelitolimod in Combination with Pembrolizumab in Anti-PD-1 Treatment-Naïve Advanced Melanoma.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: April 03, 2025
Similar Doctors
Expertise in
14
conditions
Expertise in
14
conditions
Referral may be required

Office

1700 6th Ave S, 
Irondale, AL 
 (49.3 miles away)
205-934-9999
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Warner Huh is an Oncologist practicing medicine in Irondale, Alabama. Dr. Huh is highly rated in 14 conditions, according to our data. His clinical expertise encompasses Cervical Cancer, Ovarian Cancer, Vaginal Cancer, Tubal Ligation, and Endoscopy. Dr. Huh is currently accepting new patients.

Expertise in
23
conditions
Dr. Andres Torres
Hematology | Oncology
Expertise in
23
conditions
Dr. Andres Torres
Hematology | Oncology
Referral may be required

UAB Hospital Birmingham

619 19th St S, 
Birmingham, AL 
 (57.3 miles away)
205-996-6074
Languages Spoken:
English
See accepted insurances

Andres Torres is a Hematologist and an Oncologist practicing medicine in Birmingham, Alabama. Dr. Torres is highly rated in 23 conditions, according to our data. His clinical expertise encompasses Hodgkin Lymphoma, Breast Cancer, Non-Hodgkin Lymphoma, Classical Hodgkin Lymphoma, and Bone Marrow Aspiration.

Expertise in
12
conditions
Expertise in
12
conditions
Referral may be required

Office

1700 6th Ave S, 
Irondale, AL 
 (49.3 miles away)
205-934-4986
Experience:
18+ years
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Rebecca Arend is an Oncologist practicing medicine in Irondale, Alabama. She has been practicing medicine for over 18 years. Dr. Arend is highly rated in 12 conditions, according to our data. Her clinical expertise encompasses Ovarian Cancer, Endometrial Cancer, Ovarian Carcinosarcoma, and Virilizing Ovarian Tumor. Dr. Arend is currently accepting new patients.

Frequently Asked Questions about Dr. Robert M. Conry

How do I make an appointment with Dr. Robert M. Conry?

You can book an appointment with Dr. Robert M. Conry by calling their office at 256-238-1011. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Robert M. Conry a top-rated expert for Melanoma?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Robert M. Conry is classified as an Elite expert for Melanoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Robert M. Conry specialize in?

While Dr. Robert M. Conry is a Oncology, they have specific expertise in Melanoma, Adult Soft Tissue Sarcoma, and Rhabdomyosarcoma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.

Does Dr. Robert M. Conry participate in research or clinical trials?

Yes. Dr. Robert M. Conry has published 45 articles and abstracts on conditions like Melanoma. You can view a list of Dr. Robert M. Conry's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Robert M. Conry accept my insurance?

Dr. Robert M. Conry accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 256-238-1011 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Conry's expertise for a condition
ConditionClose
View All 14 Distinguished Conditions
View All 34 Advanced Conditions
View All 101 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile